Aurinia Pharmaceuticals Inc.
US ˙ NasdaqGM ˙ CA05156V1022

SecurityAUPH / Aurinia Pharmaceuticals Inc.
InstitutionFranklin Resources Inc
Latest Disclosed Ownership132,507 shares
Latest Disclosed Value $ 1,963,754
Franklin Resources Inc reports 0.04% decrease in ownership of AUPH / Aurinia Pharmaceuticals Inc.

On May 13, 2026 - Franklin Resources Inc filed a 13F-HR form disclosing ownership of 132,507 shares of Aurinia Pharmaceuticals Inc. (US:AUPH) valued at $1,963,754 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 132,563 shares of Aurinia Pharmaceuticals Inc.. This represents a change in shares of -0.04% during the quarter. The current value of the position is $2,076,385 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 132,507 -56 -0.04 1,964 -7.14 0.0001
2026-02-11 2025-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 132,563 5,057 3.97 2,114 50.14 0.0005
2025-11-13 2025-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 127,506 18,047 16.49 1,409 51.89 0.0004
2025-08-12 2025-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 109,459 16,538 17.80 927 24.10 0.0002
2025-05-13 2025-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 92,921 0 0.00 747 -10.43 0.0002
2025-02-12 2024-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 92,921 72,668 358.80 834 479.17 0.0002
2024-11-27 2024-09-30 13F/A-1 AURINIA PHARMACEUTICALS COM 05156V102 20,253 -75,024 -78.74 144 -73.53 0.0000
2024-11-12 2024-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 20,253 -75,024 144 0.0000
2024-08-14 2024-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 95,277 12,257 14.76 544 31.08 0.0002
2024-05-13 2024-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 83,020 -97 -0.12 416 -44.44 0.0001
2024-02-09 2023-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 83,117 -4,031 -4.63 747 10.34 0.0003
2023-11-13 2023-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 87,148 -1,116 -1.26 677 -20.73 0.0003
2023-08-11 2023-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 88,264 88,264 854 0.0004
2021-05-13 2021-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 0 -38,800 -100.00 0 -100.00
2021-02-10 2020-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 38,800 13,300 52.16 535 42.67 0.0002
2020-11-12 2020-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 25,500 -1,133,100 -97.80 375 -98.06 0.0002
2020-08-13 2020-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 1,158,600 -101,000 -8.02 19,302 5.61 0.0099
2020-05-13 2020-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 1,259,600 -68,400 -5.15 18,277 -32.07 0.0122
2020-03-11 2019-12-31 13F/A-1 AURINIA PHARMACEUTICALS COM 05156V102 1,328,000 -79,500 -5.65 26,905 257.97 0.0141
2020-02-12 2019-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 1,328,000 -79,500 26,905 3,398.4699
2019-11-14 2019-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 1,407,500 0 0.00 7,516 -18.84 0.0041
2019-08-14 2019-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 1,407,500 -205,400 -12.73 9,261 -11.67 0.0049
2019-05-15 2019-03-31 13F/A-1 AURINIA PHARMACEUTICALS COM 05156V102 1,612,900 -225,600 -12.27 10,484 -16.39 0.0056
2019-05-14 2019-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 1,612,900 -225,600 10,484
2019-02-12 2018-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 1,838,500 0 0.00 12,539 2.71 0.0076
2018-11-13 2018-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 1,838,500 105,300 6.08 12,208 25.11 0.0061
2018-08-14 2018-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 1,733,200 68,800 4.13 9,758 12.97 0.0050
2018-05-10 2018-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 1,664,400 0 0.00 8,638 14.56 0.0044
2018-02-14 2017-12-31 13F AURINIA PHARMACEUTICALS COM 05156V102 1,664,400 414,400 33.15 7,540 -3.80 0.0036
2017-11-13 2017-09-30 13F AURINIA PHARMACEUTICALS COM 05156V102 1,250,000 0 0.00 7,838 2.28 0.0038
2017-08-10 2017-06-30 13F AURINIA PHARMACEUTICALS COM 05156V102 1,250,000 0 0.00 7,663 -16.48 0.0038
2017-05-12 2017-03-31 13F AURINIA PHARMACEUTICALS COM 05156V102 1,250,000 1,250,000 9,175 0.0047
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.